Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy | Zendy

Karen Johnson | Zendy; Aaron K. Aragaki | Zendy; Rebecca D. Jackson | Zendy; Alex P. Reiner | Zendy; Per Morten Sandset | Zendy; Jan Rosing | Zendy; Anders Erik Astrup Dahm | Zendy; Frits R. Rosendaal | Zendy; JoAnn E. Manson | Zendy; Lisa W. Martin | Zendy; Simin Liu | Zendy; Lewis H. Kuller | Zendy; Mary Cushman | Zendy; Jacques E. Rossouw | Zendy

Open Access

Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy

Author(s) -

Karen Johnson,

Aaron K. Aragaki,

Rebecca D. Jackson,

Alex P. Reiner,

Per Morten Sandset,

Jan Rosing,

Anders Erik Astrup Dahm,

Frits R. Rosendaal,

JoAnn E. Manson,

Lisa W. Martin,

Simin Liu,

Lewis H. Kuller,

Mary Cushman,

Jacques E. Rossouw

Publication year - 2015

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.306905

Subject(s) - estrogen , progestin , medicine , risk factor , endocrinology , hormone therapy , oncology , breast cancer , cancer

To examine whether tissue factor pathway inhibitor or acquired activated protein C (APC) resistance influences the increased risk of coronary heart disease (CHD) due to estrogen plus progestin therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Address

About

Learn

Download the Zendy App

Discover

Explore